Startups and Spinouts
GEN's Biotech Boulevard highlights new entrepreneurial biotech firms based all over the globe. These unique companies are developing breakthrough products that will expand and enhance the biotech industry.
Discover, invest, and collaborate with these industry leaders of tomorrow.
Explore Biotech Boulevard. It's paved with opportunities!
Ablexis is a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative next-generation platform for the efficient discovery and development of the next wave of human therapeutic antibodies. Ablexis is commercializing the AlivaMab Mouse platform through partnering strategies that provide broad, non-exclusive access with no target or field-of-use restrictions.
Accera is a privately-held, commercial-stage, healthcare company focused on the discovery, development and in-licensing of innovative therapeutics to treat Central Nervous System (CNS) disorders.
Activiomics is a spin-out company from the Barts Cancer Institute founded in 2009. According to the company, its mass spectrometry based approach enables the quantification of thousands of phosphorylation events from a given tissue sample to identify subsequent biomarkers of response, enabling the development of future diagnostics. Activiomics is using primary breast and kidney cancer samples to generate proof of concept data and high value data packages for predictive and prognostic markers of disease.
Adynxx is a clinical stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.
Afraxis is discovering and developing drugs to treat rare and neglected diseases through the modulation of p21-activated kinase (PAK). Afraxis' initial indication of interest is Fragile X syndrome with expansion into other diseases of the central nervous system, including schizophrenia and autism spectrum disorders. PAK is also implicated in cancer, including Neurofibromatosis, a rare form of cancer for which there are no approved drugs. Inhibiting PAK activity has the potential to induce significant anti-tumor activity.
Alcresta is developing and commercializing innovative enzyme-based nutritional products that improve patient health and manage disease for infants, older adults and patients battling acute or chronic conditions. Leveraging its existing proprietary platform of nutritional products and medical devices, Alcresta has developed a lead program designed to improve the delivery, digestion and absorption of long-chain polyunsaturated fatty acids (including omega-3 and omega-6) to support pediatric growth and development, help strengthen the immune system, accelerate the recovery of patients battling acute or chronic conditions, and enhance active adult nutrition.
AliveCor aims to provide medical professionals, patients (be they human or animal), and consumers worldwide with mobile-powered devices, data, and analysis to identify, prevent, and treat life-altering diseases from anywhere in the world. As a first offering, AliveCor has developed a clinical-quality, low-cost ECG recorder that enables patients to monitor their heart health anywhere, at any time and provides physicians with a more comprehensive assessment. The AliveCor smartphone ECG is designed to work in conjunction with a variety of mobile platforms, including iPhone, iPad, and Android devices.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. The company was founded in 2011 by industry leaders with a proven track record of success in protein therapeutic design and development. Allena is leveraging its leadership team's combined operational expertise in manufacturing, formulation and non-systemic protein delivery.
AMSilk is the first company to manufacture spider silk, a high performance protein that can be used for medical devices, wound healing, pharmaceutical products and fibers. The company's unique biotechnological process, invented at the Technische Universität München, has been scaled to industrial size for ton-scale production. AMSilk's spider silk retains the performance properties of natural spider silk, is biocompatible and can be processed into films, coatings, foams, nonwovens and fibers. AMSilk is developing several wound treatments and technical fibers (Biosteel® ) for medical and ballistic textiles.
Apexigen is a biotherapeutic development company advancing antibody drug candidates for the treatment of cancer and other serious diseases. The pipeline is led by APX005, an antibody that both exerts direct anti-tumor actions and activates an anti-tumor immune response. Four other product candidates are currently under development through collaborations. The company’s proprietary rabbit-derived humanized antibody technology platform enables the discovery of a broad diversity of antibodies to a target antigen. This great diversity of antibodies enables the discovery of antibodies with rare or specific biological properties, which may become the next generation of breakthrough therapeutics. Apexigen is employing its strategy to develop innovative bio-therapeutics, advance its product pipeline, and see that important new therapies are made available to patients.